CommercialCoverageMedium impact
08.00.55l, Omalizumab (Xolair®)
Independence Blue Cross·Allergy & Immunology, Pulmonology, Dermatology +2 more·Pharmacy
Effective date
Jan 6, 2025
We identified it
Jun 19, 2026
Summary
The Omalizumab (Xolair®) pharmacy policy has been updated with changes to coverage and/or reimbursement position effective January 6, 2025. This affects billing and coverage rules for this asthma and chronic hives medication under commercial insurance plans.
Action Required
Immediately: Review the full policy details at the provided URL to understand specific coverage and reimbursement changes for Omalizumab (Xolair®). Update billing procedures and prior authorization requirements as specified in the complete policy. Notify providers who prescribe this medication for asthma and chronic urticaria patients.